Objectives: The purpose of this study was to evaluate 1-year results and influencing factors of carotid artery stenting (CAS) before open heart surgery (OHS).
| I N TR ODU C TI ON
The coexistence of carotid disease is frequently seen in patients scheduled for open heart surgery (OHS); it adds complexity to surgical management [1, 2] . Even if asymptomatic, patients with significant carotid stenosis face a high risk of perioperative stroke while undergoing OHS [3] . Thus, planning appropriate treatment for patients with severe carotid stenosis before OHS is an important clinical issue. With recent advancements in percutaneous intervention and embolic protection devices, carotid artery stenting (CAS) has demonstrated an inspiring procedural and long-term result compared with carotid endarterectomy (CEA), especially in patients with high surgical risks including those with severe coronary artery disease [4, 5] . Some observational studies have shown that synchronous or staged CAS before OHS may be a more effective method for patients with coexisting carotid and cardiac disease compared with combined CEA and OHS [6] [7] [8] . However, in the absence of randomized trails, the safety and efficacy of CAS followed *Hui Dong and Wuqiang Che equally contributed to the study as first coauthors.
by OHS remains in dispute. Moreover, the factors influencing the clinical outcomes of this treatment strategy remain unknown. The purpose of this study was to evaluate the 1-year results and influencing factors of CAS before OHS.
| M A TE RI A L S A ND M E TH ODS

| Patient population
In this single-center prospective study, we analyzed 323 consecutive patients scheduled to undergo CAS followed by OHS from January 2005 to December 2012 at Fuwai Hospital. Indication for CAS was defined as carotid artery diameter reduction of >60% (symptomatic) or >80% (asymptomatic), while indication for OHS included symptomatic severe coronary artery disease not eligible for percutaneous revascularization and symptomatic valvular heart disease. Exclusion criteria included (1) intolerance to heparin and antiplatelet drugs, (2) the presence of intraluminal carotid artery thrombus, (3) chronic carotid total occlusion, (4) history of ischemic major stroke within three months, (5) severe co-morbidity in patients not tolerable to percutaneous intervention, and (6) any other illness that impeded their ability to provide informed consent. This study was approved by the ethics committee of Fuwai Hospital, and written informed consent was provided by all patients.
| Interventional and cardiac procedure
Before the CAS procedure, patients received their regular antihypertensive medications on the morning of the procedure, with the exception of beta-blockers. Beta-blockers were discontinued the day of the procedure in an attempt to mitigate baroreceptor stimulationrelated bradycardia and hypotension caused by balloon inflation and stent implantation. CAS procedures were all performed via femoral access with accompanying local anesthesia at the access site. An 8F introducer sheath was inserted and heparin (100 U/kg) was administered. Then, an 8F MPA1 guiding catheter (Boston Scientific, Massachusetts, USA) was placed proximal to the target lesion. Distal embolic protection was used in most patients during CAS procedures.
Devices included the Filterwire EZ system (Boston Scientific, Massachusetts, USA) and the Spider RX filter system (Ev3 Inc., California, USA). If the diameter reduction was 85%, the lesion was pre-dilated using an undersized balloon. Balloon expandable stents were deployed in lesions located in the orifice of the carotid common artery, while self-expanding stents were implanted in more distal lesions. If necessary, the lesion was post-dilated to achieve a residual stenosis 30% after stent deployment. Atropine (0.5-1.0 mg) was administered intravenously in advance of the procedure to avoid or attenuate bradycardia in patients with lesions on the carotid bulb.
During the procedure, atropine was repeated for patients who developed a >20 beats/min drop in their heart rate during balloon dilatation or stent deployment. If hypotension occurred, patients received 2-3 mg of dopamine and rapid administration of additional fluids.
Following the procedure, patients were monitored for changes in hemodynamics and other clinical signs. All patients were evaluated independently by a neurologist prior to, during and after the procedure. Electrocardiogram (ECG) monitoring was continuous during the first 24 hr following the procedure and throughout the hospitalization period in the case of unexplained chest pain.
The OHS procedures included coronary artery bypass graft placement, valve replacement, aneurysm resection, and modified Maze procedure for atrial fibrillation. All were performed according to standard practice.
| Periprocedural anticoagulation protocol
For patients who underwent simultaneous CAS and OHS, aspirin (100 mg/day) was administered for at least 3 days until the hybrid procedure was performed, and clopidogrel (75 mg/day) was administered for at least 3 days until 3 days before the hybrid procedure. Postoperative anticoagulation included the use of low molecular weight heparin (100 U/kg) twice daily for 3 days for stent-thrombosis prophylaxis; additionally, clopidogrel (75 mg/day) and aspirin (100 mg/day)
were taken for at least 3 months after the first day of extubation. Aspirin was continued for the remainder of the patients' lives.
If patients underwent staged CAS and OHS, aspirin (100 mg/day) and clopidogrel (75 mg/day) were administered at least 3 days before CAS. Clopidogrel was discontinued 3 days before OHS. However, patients continued to receive aspirin until OHS was performed. The same post-operative pharmacological protocol was applied as in patients who underwent the hybrid procedure.
| Endpoints and follow up
The primary endpoint was a composite of major stroke, myocardial infarction (MI) or death within 1 year after CAS. The secondary endpoints included acute kidney injury (AKI), contrast-induced nephropathy (CIN), and a composite of major stroke, MI, or death from CAS to 30 days after OHS, and individual components of the primary endpoints and minor stroke within 30 days and 1-year follow up. A stroke was considered to be major if patients had a modified Rankin score of 4 at 30 days after the onset of symptoms [9] . MI was defined by the presence of at least two of the following three criteria: specific cardiac enzymes more than twice the upper limit of normal, history of chest discomfort for at least 30 min, or the development of specific abnormalities (e.g., Q waves) on a standard 12-lead electrocardiograph. AKI was diagnosed according to the RIFLE criteria (serum creatinine increase of 2-3 times baseline or a glomerular filtration rate decrease of >50% and/or urine output <0.5 ml/kg/h for 12 hr) [10] . CIN was defined as a relative increase in serum creatinine from baseline of 25% or an absolute increase of 44.2 lmol/l (0.5 mg/dl) within 72 hr after the interventional procedure [11] .
Telephone or clinical interviews were conducted at 1, 6, and 12 months after OHS by a dedicated research coordinator. In the case of an event, hospital notes or death certificates were issued when 
| Statistical analysis
Continuous variables were presented as the mean 6 standard deviation, while categorical data were given as counts and percentages. Multivariate logistic regression and Cox regression analyses were performed by stepwise selection of variables and used to identify the factors influencing the 30-day and 1-year outcomes, respectively. Multivariate odds ratios (OR) and hazard ratios (HR) were reported with 95% confidence intervals (CIs).Variables of baseline characteristics including age, sex, hypertension, hyperlipemia, diabetes mellitus, current smoking, previous stroke, three-vessel disease, left main involvement, previous MI, valvular heart disease, congestive heart failure, renal insufficiency, chronic pulmonary disease, symptomatic carotid stenosis, and procedural characteristics (simultaneous bilateral CAS, simultaneous percutaneous intervention of other peripheral arteries, number of grafts, and usage of the left internal mammary artery graft), as well as the interval between CAS and OHS (5 days or >5 days), were evaluated. The Kaplan-Meier method was used to compute the 1-year rate of freedom from the primary endpoint, and the log-rank test was used to compare groups. All probability values were two-sided, and a P value <0.05 was considered to indicate significance. All analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, USA).
| RE S U L TS
| Baseline clinical characteristics
In total, 263 (81.4%) men and 60 (18.6%) women were included, with a mean age of 65.2 6 7.3 years. One hundred twenty-seven (39.3%) patients had symptomatic carotid stenosis, 73 (22.6%) had significant bilateral carotid stenosis, and 18 (5.6%) had contralateral carotid occlusion. The other baseline clinical characteristics of all 323 patients are summarized in Table 1 .
| Interventional procedure
The characteristics of the interventional procedures are shown in Table   2 . The overall procedural success rate of CAS was 99.4% (321/323).
Cerebral protection devices were used in 320 patients (99.1%). A total of 392 stents including five (1.3%) balloon expandable stents and 387 (98.7%) self-expanding stents were implanted in 388 carotid lesions.
The mean angiographic degree of stenosis was reduced from 86. Values are the mean 6 SD or n (%). Abbreviations: MI, myocardial infarction; PCI, percutaneous coronary intervention. a Baseline serum creatinine 1.5 mg/dl. b Patients were considered to be symptomatic if they had suffered from a carotid distribution transient ischemic attack or a minor stroke in the preceding 6 months. Values are n (%).
could not pass through the lesion. The mean use of contrast was 105 6 19.9 ml in all 323 patients.
| Cardiac surgery
The mean interval time between CAS and OHS was 22. of these, 68 procedures were accomplished without cardiopulmonary bypass (off-pump). The characteristics of OHS are listed in Table 3 .
| Thirty-day endpoints
Clinical outcomes from CAS to 30 days after OHS are shown in Table   4 . During the period between CAS and OHS, 18 adverse events occurred, including one (0.3%) ipsilateral major stroke resulting from stent thrombosis, five (1.5%) minor strokes, three (0.9%) MI, one death because of a massive MI and nine (2.8%) AKI. Cardiac surgery was performed in 321 patients. Four (1.2%) patients died within 30 days after OHS, including one neurological death resulting from a major contralateral stroke, one cardiac death resulting from a massive MI and congestive heart failure and two general deaths. Four patients had a nonfatal major stroke (two major contralateral strokes and two major ipsilateral stroke), two patients suffered from minor stroke, and seven patients had AKI. In total, the incidence of the primary endpoint, the composite of major stroke and any death, minor stroke, AKI, CIN from the time of CAS to 30 days post-OHS was 4.6, 3.1, 2.2, 5.0, and 9.9%, respectively.
Logistic regression analysis revealed that an interval of 5 days between CAS and OHS (OR, 4.51, 95% CI, 1.52-13.36; P 5 0.007) and congestive heart failure (OR, 5.32, 95% CI, 1.63-17.43; P 5 0.006)
were identified as independent risk factors for the primary endpoint rate from CAS to 30 days after OHS.
| Twelve-month endpoints
Clinical outcomes within 1 year after CAS are shown in Table 5 . Intensive care stay, (hr) 54.6 6 61.4
Post-operative length of stay, (days) 9.2 6 3.5
Values are the mean 6 SD or n (%). Abbreviations: OHS, open heart surgery; CABG, coronary artery bypass graft; LIMA, left internal mammary artery. 
| D I SCUSSION
The cause of perioperative stroke related to cardiac surgery is multifactorial, including atheroemboli dislodged from the atherosclerotic aorta during cannulation, clamping, or placement of proximal anastomoses, etc. Of these, significant carotid stenosis may be the responsible mechanism and results in one-third of all perioperative strokes [1] . with CABG. In our study, patients also experienced a low incidence of combined major stroke, MI, or death. The incidence of the primary endpoint from time of CAS to 30 days post-OHS and 1-year after CAS was 4.6% and 5.6%, respectively. Major stroke occurred in only one patient (0.3%) during the period between CAS and OHS, despite the fact that 18.9% of patients underwent bilateral carotid stenting. Moreover, the total incidence of MI in the perioperative period is 2.2%, even though three-vessel diseases and left main involvement were seen in 54.3% and 51.6% of patients, respectively. After the perioperative period, the incidence of adverse events was relatively low. Thus, our 1-year results corroborated the findings from Van der Heyden's prospective series [15] and were similar to those comparing CAS plus OHS with CEA plus OHS [6] [7] [8] .
To date, the factors influencing the clinical outcomes of CAS and OHS have not been studied. Our study analyzed the influencing factors for major cardiovascular events and showed that after adjusting for other baseline information and procedural characteristics, an interval of 5 days between CAS and OHS, congestive heart failure, and renal insufficiency could independently predict the incidence of combined major stroke, MI and death from any cause. Additionally, patients with an interval of >5 days between CAS and OHS had significantly higher rates of 1-year rate of freedom from combined major stroke, MI and death from any cause than those with an interval of 5 days between CAS and OHS (96.2% vs. 85.6%, P 5 0.001). This study indicated that patients with a shorter interval between CAS and OHS (5 days) and poorer heart and renal function may have a worse prognosis. An interval time of >5 days between CAS and OHS, if the conditions of patients permitted, could improve 1-year results.
| S T U DY LI M I TA TI ON S
There were several limitations in our study. First, this prospective, nonrandomized study cannot be compared with other trials of CEA with OHS because of the differing composition of patient populations. Second, cost-effectiveness (hospital costs, in-hospital stay, patient readmission for the second procedure, etc.) was also not evaluated in this study.
| C ONC LUSI ON
In conclusion, CAS followed by OHS may be a safe and effective treatment for patients with concomitant carotid and cardiac disease, given the low periprocedural and 12-month complication rates observed in this study. Patients with an interval of 5 days between CAS and OHS, congestive heart failure, and renal insufficiency have a higher rate of combined major stroke, MI, and any death during 1-year follow up. Further studies including large randomized trials are needed to verify these findings.
